Correlation Between Verve Therapeutics and Adaptive Biotechnologies

Can any of the company-specific risk be diversified away by investing in both Verve Therapeutics and Adaptive Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Verve Therapeutics and Adaptive Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Verve Therapeutics and Adaptive Biotechnologies Corp, you can compare the effects of market volatilities on Verve Therapeutics and Adaptive Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Verve Therapeutics with a short position of Adaptive Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Verve Therapeutics and Adaptive Biotechnologies.

Diversification Opportunities for Verve Therapeutics and Adaptive Biotechnologies

0.25

Correlation Coefficient

Verve Therapeutics  Adaptive Biotechnologies

Modest diversification

The 3 months correlation between Verve and Adaptive is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Verve Therapeutics and Adaptive Biotechnologies Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptive Biotechnologies and Verve Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Verve Therapeutics are associated (or correlated) with Adaptive Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptive Biotechnologies has no effect on the direction of Verve Therapeutics i.e., Verve Therapeutics and Adaptive Biotechnologies go up and down completely randomly.

Pair Corralation between Verve Therapeutics and Adaptive Biotechnologies

Given the investment horizon of 90 days Verve Therapeutics is expected to under-perform the Adaptive Biotechnologies. But the stock apears to be less risky and, when comparing its historical volatility, Verve Therapeutics is 1.18 times less risky than Adaptive Biotechnologies. The stock trades about -0.02 of its potential returns per unit of risk. The Adaptive Biotechnologies Corp is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  531.00  in Adaptive Biotechnologies Corp on September 2, 2024 and sell it today you would earn a total of  63.00  from holding Adaptive Biotechnologies Corp or generate 11.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Verve Therapeutics  vs.  Adaptive Biotechnologies Corp

Verve Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Verve Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Verve Therapeutics is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Adaptive Biotechnologies

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Adaptive Biotechnologies unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Verve Therapeutics and Adaptive Biotechnologies

The main advantage of trading using opposite Verve Therapeutics and Adaptive Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Verve Therapeutics position performs unexpectedly, Adaptive Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will offset losses from the drop in Adaptive Biotechnologies' long position.

The idea behind Verve Therapeutics and Adaptive Biotechnologies Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.